» Articles » PMID: 29737630

A Framework for Identifying Treatment-covariate Interactions in Individual Participant Data Network Meta-analysis

Overview
Date 2018 May 9
PMID 29737630
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Stratified medicine seeks to identify patients most likely to respond to treatment. Individual participant data (IPD) network meta-analysis (NMA) models have greater power than individual trials to identify treatment-covariate interactions (TCIs). Treatment-covariate interactions contain "within" and "across" trial interactions, where the across-trial interaction is more susceptible to confounding and ecological bias.

Methods: We considered a network of IPD from 37 trials (5922 patients) for cervical cancer (2394 events), where previous research identified disease stage as a potential interaction covariate. We compare 2 models for NMA with TCIs: (1) 2 effects separating within- and across-trial interactions and (2) a single effect combining within- and across-trial interactions. We argue for a visual assessment of consistency of within- and across-trial interactions and consider more detailed aspects of interaction modelling, eg, common vs trial-specific effects of the covariate. This leads us to propose a practical framework for IPD NMA with TCIs.

Results: Following our framework, we found no evidence in the cervical cancer network for a treatment-stage interaction on the basis of the within-trial interaction. The NMA provided additional power for an across-trial interaction over and above the pairwise evidence. Following our proposed framework, we found that the within- and across-trial interactions should not be combined.

Conclusion: Across-trial interactions are susceptible to confounding and ecological bias. It is important to separate the sources of evidence to check their consistency and identify which sources of evidence are driving the conclusion. Our framework provides practical guidance for researchers, reducing the risk of unduly optimistic interpretation of TCIs.

Citing Articles

Comparative efficacy and complications of long-acting and intermediate-acting insulin regimens for adults with type 1 diabetes: an individual patient data network meta-analysis.

Veroniki A, Seitidis G, Stewart L, Clarke M, Tudur-Smith C, Mavridis D BMJ Open. 2022; 12(11):e058034.

PMID: 36332950 PMC: 9639076. DOI: 10.1136/bmjopen-2021-058034.


Challenges of modelling approaches for network meta-analysis of time-to-event outcomes in the presence of non-proportional hazards to aid decision making: Application to a melanoma network.

Freeman S, Cooper N, Sutton A, Crowther M, Carpenter J, Hawkins N Stat Methods Med Res. 2022; 31(5):839-861.

PMID: 35044255 PMC: 9014691. DOI: 10.1177/09622802211070253.


Individual Patient Data Meta-Analysis and Network Meta-Analysis.

Freeman S Methods Mol Biol. 2021; 2345():279-298.

PMID: 34550597 DOI: 10.1007/978-1-0716-1566-9_17.


Statistical analyses and quality of individual participant data network meta-analyses were suboptimal: a cross-sectional study.

Gao Y, Shi S, Li M, Luo X, Liu M, Yang K BMC Med. 2020; 18(1):120.

PMID: 32475340 PMC: 7262764. DOI: 10.1186/s12916-020-01591-0.


Individual participant data meta-analysis of intervention studies with time-to-event outcomes: A review of the methodology and an applied example.

de Jong V, Moons K, Riley R, Tudur Smith C, Marson A, Eijkemans M Res Synth Methods. 2019; 11(2):148-168.

PMID: 31759339 PMC: 7079159. DOI: 10.1002/jrsm.1384.


References
1.
. Neoadjuvant chemotherapy for locally advanced cervical cancer: a systematic review and meta-analysis of individual patient data from 21 randomised trials. Eur J Cancer. 2003; 39(17):2470-86. DOI: 10.1016/s0959-8049(03)00425-8. View

2.
Riley R, Lambert P, Staessen J, Wang J, Gueyffier F, Thijs L . Meta-analysis of continuous outcomes combining individual patient data and aggregate data. Stat Med. 2007; 27(11):1870-93. DOI: 10.1002/sim.3165. View

3.
Dias S, Sutton A, Ades A, Welton N . Evidence synthesis for decision making 2: a generalized linear modeling framework for pairwise and network meta-analysis of randomized controlled trials. Med Decis Making. 2012; 33(5):607-17. PMC: 3704203. DOI: 10.1177/0272989X12458724. View

4.
Thompson S, Higgins J . How should meta-regression analyses be undertaken and interpreted?. Stat Med. 2002; 21(11):1559-73. DOI: 10.1002/sim.1187. View

5.
Lu G, Welton N, Higgins J, White I, Ades A . Linear inference for mixed treatment comparison meta-analysis: A two-stage approach. Res Synth Methods. 2015; 2(1):43-60. DOI: 10.1002/jrsm.34. View